The effect of statin therapy on testosterone levels in subjects consulting for erectile dysfunction.
BACKGROUND
Previous clinical studies on effect of statins treatment on testosterone (T) levels have produced mixed results.


OBJECTIVE
The aim of the present study is to evaluate the association between statin therapy and hormonal parameters in a large series of subjects seeking medical care at our unit for erectile dysfunction (ED).


METHODS
A consecutive series of 3,484 (mean age 51.6 + or - 13.1 years) patients with ED was studied.


METHODS
Several hormonal and biochemical parameters were investigated, along with ANDROTEST structured interview measuring hypogonadism-related symptoms.


RESULTS
Among the patients studied, 244 (7%) patients were being treated with statins. After adjustment for confounding factors (including body mass index and Progetto Cuore cardiovascular (CV) risk engine score), both total and calculated free testosterone levels were significantly lower in subjects taking statins, when compared to the rest of the sample (hazard ratio [HR] = 0.93 [0.90; 0.96] and 0.26 [0.01; 0.18] for each decrement of total T and calculated free T, respectively; both P < 0.0001). The use of statins was also associated with a reduced testis volume and a higher prevalence of hypogonadism-related symptoms and signs, as assessed by higher ANDROTEST score (HR = 1.12 [1.03; 1.21]; P < 0.01 after adjustment for confounders). Follicle-stimulating hormone levels were significantly higher in subjects treated with statins when compared to the rest of the sample, while there was a trend toward higher luteinizing hormone levels, but this did not reach statistical significance. The lower levels of total and calculated free T observed in subjects treated with statins were also confirmed comparing them with age-waist circumference and CV risk score matched controls. Finally, subjects being treated with statins showed lower prolactin levels when compared to the rest of the sample.


CONCLUSIONS
Our data demonstrated that statin therapy might induce an overt primary hypogonadism and should be considered as a possible confounding factor for the evaluation of testosterone levels in patients with ED.
Corona
Giovanni
G
Andrology Unit, Department of Clinical Physiopathology, University of Florence, Florence Italy.
Boddi
Valentina
V
Balercia
Giancarlo
G
Rastrelli
Giulia
G
De Vita
Giulia
G
Sforza
Alessandra
A
Forti
Gianni
G
Mannucci
Edoardo
E
Maggi
Mario
M
D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015992:Body Mass Index; D016022:Case-Control Studies; D015331:Cohort Studies; D007172:Erectile Dysfunction / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy*; D007006:Hypogonadism / Q000097:blood* / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D011388:Prolactin / Q000097:blood; D012189:Retrospective Studies; D012307:Risk Factors; D013739:Testosterone / Q000097:blood*
D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D013739:Testosterone; D011388:Prolactin